Bilateral lung cancer showing various responses to immune checkpoint inhibitors: A case report.
Hiroaki KodamaTatsuya IbeRentaro InoueTetsuya ShimadaHisashi IshiiYoichiro HamamotoPublished in: Cancer reports (Hoboken, N.J.) (2020)
Bilateral lung lesions considered to be intrapulmonary metastases have completely different responses to ICI treatment. It is necessary to consider a diagnosis of SMPLCs if lesions with different responses to antitumor therapy are observed.